header
Image from OpenLibrary

The effect of oral pre-treatment by nicorandil on the outcome of PCI in patients with ACS / Dalia Shawky Abdelmoneim ; Supervised Essam Baligh Ewis , Hussein Heshmat Kassem

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Dalia Shawky Abdelmoneim , 2018Description: 174 P. : charts , facsimiles ; 25cmOther title:
  • تأثير تناول عقار النيكورانديل عن طريق الفم فى مرحلة ما قبل البدء بالعلاج بالتدخل التاجى عن طريق الجلد فى المرضى الذين يعانون من متلازمة الشريان التاجى الحادة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Cardiology Summary: Coronary artery disease (CAD) is considered to be the most common disease worldwide and has the highest mortality rate in the western countries. 1 In recent years, percutaneous coronary intervention (PCI) has become the principal means of revascularization in patients with CAD. 2-3 No reflow or slow flow occurs in 3-4% of all percutaneous coronary interventions. The current available approaches to prevent and treat no-reflow include IIBIIIA blockers, adenosine, nitroprusside, and mechanical thrombectomy aspiration devices. Nicorandil is an ATP sensitive potassium channel (KATP) open agent with the effect of nitrate. 4, 5 Intravenous nicorandil before PCI can significantly reduce the incidence of coronary slow flow after postoperative. 6, 7 nicorandil can antagonize ADP induced platelet aggregation, improve microcirculation in ischemic area and decrease no reflow phenomenon. 8 In our study, we have detected the effect of oral pre-treatment by nicorandil on the outcome of PCI in patients with ACS. The aim of the study: Primary was evaluation of post procedural no-reflow and slow flow phenomenon by evaluation TIMI flow and cTFC pre and post PCI and secondary was evaluation of peri-procedure myocardial infarction (MI) and one month major adverse cardiac events MACE
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.04.M.Sc.2018.Da.E (Browse shelf(Opens below)) Not for loan 01010110076701000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.04.M.Sc.2018.Da.E (Browse shelf(Opens below)) 76701.CD Not for loan 01020110076701000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Cardiology

Coronary artery disease (CAD) is considered to be the most common disease worldwide and has the highest mortality rate in the western countries. 1 In recent years, percutaneous coronary intervention (PCI) has become the principal means of revascularization in patients with CAD. 2-3 No reflow or slow flow occurs in 3-4% of all percutaneous coronary interventions. The current available approaches to prevent and treat no-reflow include IIBIIIA blockers, adenosine, nitroprusside, and mechanical thrombectomy aspiration devices. Nicorandil is an ATP sensitive potassium channel (KATP) open agent with the effect of nitrate. 4, 5 Intravenous nicorandil before PCI can significantly reduce the incidence of coronary slow flow after postoperative. 6, 7 nicorandil can antagonize ADP induced platelet aggregation, improve microcirculation in ischemic area and decrease no reflow phenomenon. 8 In our study, we have detected the effect of oral pre-treatment by nicorandil on the outcome of PCI in patients with ACS. The aim of the study: Primary was evaluation of post procedural no-reflow and slow flow phenomenon by evaluation TIMI flow and cTFC pre and post PCI and secondary was evaluation of peri-procedure myocardial infarction (MI) and one month major adverse cardiac events MACE

Issued also as CD

There are no comments on this title.

to post a comment.